Last reviewed · How we verify
Placebo matching Ipilimumab
This is a placebo control arm matching the dosing and administration schedule of ipilimumab, the active comparator.
This is a placebo control arm matching the dosing and administration schedule of ipilimumab, the active comparator. Used for Control arm in phase 3 clinical trials of ipilimumab-based immunotherapy regimens.
At a glance
| Generic name | Placebo matching Ipilimumab |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
In clinical trials, placebo matching ipilimumab is used as a control to maintain blinding while patients receive an inert substance with identical appearance and administration schedule to ipilimumab (a CTLA-4 inhibitor). This allows for proper assessment of ipilimumab's true efficacy by comparing outcomes against a blinded control rather than open-label or unblinded comparisons.
Approved indications
- Control arm in phase 3 clinical trials of ipilimumab-based immunotherapy regimens
Common side effects
Key clinical trials
- Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (PHASE3)
- Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) (PHASE3)
- Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (PHASE3)
- Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer (PHASE3)
- Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma (PHASE2)
- Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone (PHASE3)
- Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matching Ipilimumab CI brief — competitive landscape report
- Placebo matching Ipilimumab updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI